Literature DB >> 15490061

Surgical management of amiodarone-associated thyrotoxicosis: Mayo Clinic experience.

Scott G Houghton1, David R Farley, Michael D Brennan, Jon A van Heerden, Geoffrey B Thompson, Clive S Grant.   

Abstract

Amiodarone-associated thyrotoxicosis (AAT) is often poorly tolerated owing to underlying cardiac disease, and it is frequently refractory to conventional medical treatment. The goal of this study was to describe the patient characteristics, management, and outcomes of all the patients treated surgically for AAT at a single institution. We conducted a retrospective chart review of all patients managed surgically for AAT (April 1985 through November 2002) at the Mayo Clinic in Rochester, Minnesota. Altogether, 29 men and 5 women, ages 39 to 85 years (median 60 years), treated with amiodarone for 3 to 108 months underwent near-total or total thyroidectomy. Frequent symptoms were worsening heart failure, fatigue, weight loss, and tremor. Altogether, 12 patients failed medical management of their AAT, and 21 received no preoperative medical therapy. One patient had been successfully managed medically but required definitive treatment. Common indications for operation were the need to remain on amiodarone, cardiac decompensation, medically refractory disease, and severe symptoms, both hyperthyroid and cardiac, necessitating prompt resolution. The median+/-SD American Society of Anesthesiologists (ASA) classification (1 = healthy through 5 = moribund) was 3.00+/-0.58. A total of 27 specimens had histology consistent with AAT. Complications included death (n = 3), rehospitalization (n = 3), symptomatic hypocalcemia (n = 2), pneumonia (n = 2), cervical hematoma (n = 1), prolonged ventilatorywean (n = 1), and stroke (n = 1); one patient developed hypotension, adult respiratory distress syndrome, and sepsis. Of the 31 surviving patients, 25 (80%) remained on amiodarone postoperatively. The median follow-up was 29 months, at which time all surviving patients were free of hyperthyroid symptoms. Thyroidectomy is an effective treatment for AAT but has a high incidence of perioperative morbidity and mortality. The cardiovascular co-morbidities and high operative risk in this group of patients may account for the increased complication rate.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15490061     DOI: 10.1007/s00268-004-7599-6

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  22 in total

Review 1.  The effects of amiodarone on the thyroid.

Authors:  E Martino; L Bartalena; F Bogazzi; L E Braverman
Journal:  Endocr Rev       Date:  2001-04       Impact factor: 19.871

Review 2.  Amiodarone-induced thyrotoxicosis.

Authors:  G H Daniels
Journal:  J Clin Endocrinol Metab       Date:  2001-01       Impact factor: 5.958

3.  Surgical management of amiodarone-associated thyrotoxicosis: too risky or too effective?

Authors:  E Hamoir; M Meurisse; T Defechereux; J Joris; J Vivario; G Hennen
Journal:  World J Surg       Date:  1998-06       Impact factor: 3.352

4.  Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results of a prospective study.

Authors:  L Bartalena; S Brogioni; L Grasso; F Bogazzi; A Burelli; E Martino
Journal:  J Clin Endocrinol Metab       Date:  1996-08       Impact factor: 5.958

5.  Treatment of amiodarone associated thyrotoxicosis by simultaneous administration of potassium perchlorate and methimazole.

Authors:  E Martino; F Aghini-Lombardi; S Mariotti; M Lenziardi; L Baschieri; L E Braverman; A Pinchera
Journal:  J Endocrinol Invest       Date:  1986-06       Impact factor: 4.256

6.  Treatment of amiodarone induced hyperthyroidism with potassium perchlorate and methimazole during amiodarone treatment.

Authors:  L J Reichert; H A de Rooy
Journal:  BMJ       Date:  1989-06-10

7.  Iodine kinetic studies during amiodarone treatment.

Authors:  R H Rao; V R McCready; G S Spathis
Journal:  J Clin Endocrinol Metab       Date:  1986-03       Impact factor: 5.958

8.  Amiodarone-induced thyrotoxicosis: clinical presentation and expanded indications for thyroidectomy.

Authors:  D C Mulligan; C R McHenry; W Kinney; C B Esselstyn
Journal:  Surgery       Date:  1993-12       Impact factor: 3.982

9.  Amiodarone iodine-induced hypothyroidism: risk factors and follow-up in 28 cases.

Authors:  E Martino; F Aghini-Lombardi; S Mariotti; L Bartalena; M Lenziardi; C Ceccarelli; G Bambini; M Safran; L E Braverman; A Pinchera
Journal:  Clin Endocrinol (Oxf)       Date:  1987-02       Impact factor: 3.478

10.  Nongoitrous (type I) amiodarone-associated thyrotoxicosis: evidence of follicular disruption in vitro and in vivo.

Authors:  M D Brennan; D Z Erickson; J A Carney; R S Bahn
Journal:  Thyroid       Date:  1995-06       Impact factor: 6.568

View more
  18 in total

1.  Cost effectiveness of a pharmacist-led information technology intervention for reducing rates of clinically important errors in medicines management in general practices (PINCER).

Authors:  Rachel A Elliott; Koen D Putman; Matthew Franklin; Lieven Annemans; Nick Verhaeghe; Martin Eden; Jasdeep Hayre; Sarah Rodgers; Aziz Sheikh; Anthony J Avery
Journal:  Pharmacoeconomics       Date:  2014-06       Impact factor: 4.981

Review 2.  Total thyroidectomy for amiodarone-associated thyrotoxicosis in patients with severe cardiac disease.

Authors:  Jenny Gough; Ian R Gough
Journal:  World J Surg       Date:  2006-11       Impact factor: 3.352

3.  2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction.

Authors:  Luigi Bartalena; Fausto Bogazzi; Luca Chiovato; Alicja Hubalewska-Dydejczyk; Thera P Links; Mark Vanderpump
Journal:  Eur Thyroid J       Date:  2018-02-14

4.  Successful Pretreatment Using Plasma Exchange before Thyroidectomy in a Patient with Amiodarone-Induced Thyrotoxicosis.

Authors:  Annelies Tonnelier; Jeroen de Filette; Ann De Becker; Sophie Deweer; Brigitte Velkeniers
Journal:  Eur Thyroid J       Date:  2017-02-18

5.  Combination of minimally invasive thyroid surgery and local anesthesia associated to iopanoic acid for patients with amiodarone-induced thyrotoxicosis and severe cardiac disorders: a pilot study.

Authors:  Piero Berti; Gabriele Materazzi; Fausto Bogazzi; Carlo Enrico Ambrosini; Enio Martino; Paolo Miccoli
Journal:  Langenbecks Arch Surg       Date:  2006-11-14       Impact factor: 3.445

6.  Therapeutic Plasma Exchange in Refractory Hyperthyroidism.

Authors:  Clotilde Saïe; Cécile Ghander; Samir Saheb; Christel Jublanc; Denis Lemesle; Charlotte Lussey-Lepoutre; Laurence Leenhardt; Fabrice Menegaux; Christophe Tresallet; Camille Buffet
Journal:  Eur Thyroid J       Date:  2020-04-28

Review 7.  [Thyroid and treatment with amiodarone diagnosis, therapy and clinical management].

Authors:  Peter Mikosch
Journal:  Wien Med Wochenschr       Date:  2008

Review 8.  [Total thyroidectomy in patients with amiodarone-induced hyperthyroidism: when does the risk of conservative treatment exceed the risk of surgery?].

Authors:  C Meerwein; D Vital; M Greutmann; C Schmid; G F Huber
Journal:  HNO       Date:  2014-02       Impact factor: 1.284

9.  Thyroidectomy using monitored local or conventional general anesthesia: an analysis of outpatient surgery, outcome and cost in 1,194 consecutive cases.

Authors:  Kathryn Spanknebel; John A Chabot; Mary DiGiorgi; Kenneth Cheung; James Curty; John Allendorf; Paul LoGerfo
Journal:  World J Surg       Date:  2006-05       Impact factor: 3.352

Review 10.  Amiodarone-induced thyrotoxicosis: a review.

Authors:  Wendy Tsang; Robyn L Houlden
Journal:  Can J Cardiol       Date:  2009-07       Impact factor: 5.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.